Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

Status:	Completed
Conditions:	Arthritis, Rheumatoid Arthritis
Therapuetic Areas:	Rheumatology
Healthy:	No
Age Range:	18 - 75
Updated:	12/6/2018
Start Date:	December 20, 2016
End Date:	December 12, 2017

A Phase 2a, Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study To Assess The Efficacy And Safety Profile Of Pf-06651600 In Subjects With Moderate To Severe Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate

This is an 8 week study to assess the efficacy and safety profile of PF-06651600 in
seropositive subjects with rheumatoid arthritis with an inadequate response to methotrexate
(up to approximately 50% of subjects may also have had an inadequate response to 1 anti-TNF
biologic).

Inclusion Criteria

- Subjects between the ages of 18 and 75 years, inclusive

- Must have moderate-to-severe, active Rheumatoid Arthritis

- Must have had an inadequate response to Methotrexate

- Subjects may have received one approved TNF inhibiting biologic agent that was
inadequately effective and/or not tolerated

Exclusion Criteria

- Subjects with any acute or chronic infections or infection history

- Have acute or active chronic dermatological disorders prior to study start

- Any major illness/condition(s) or evidence of an unstable clinical condition that in
the judgment of the investigator would make the subject inappropriate for entry into
this study

- Known immunodeficiency disorder or a first degree relative with hereditary
immunodeficiency

- Any live (attenuated) vaccines or current routine household contact with anyone who
has received live (attenuated) vaccine

We found this trial at

sites

California Medical Research Associates Inc.

Northridge, California 91324

from

Northridge, CA